newsfilter
← Latest News
GlobeNewswire·

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027